Skip to main content

CORRECTION article

Front. Endocrinol., 04 June 2020
Sec. Translational Endocrinology
Volume 11 - 2020 | https://doi.org/10.3389/fendo.2020.00227
This article is part of the Research Topic Adiponectin: Friend or Foe? Toward Understanding the Complexities of Adiponectin Biology and Challenges in Pharmaceutical Development View all 9 articles

Addendum: Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women

This article is a correction to:

  1. Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women

    1. Read original article
\nYujuan Xiang,&#x;Yujuan Xiang1,2†Wenzhong Zhou,&#x;Wenzhong Zhou1,3†Xuening DuanXuening Duan4Zhimin FanZhimin Fan5Shu WangShu Wang6Shuchen Liu,Shuchen Liu1,3Liyuan Liu,Liyuan Liu1,2Fei Wang,Fei Wang1,2Lixiang Yu,Lixiang Yu1,2Fei Zhou,Fei Zhou1,2Shuya Huang,Shuya Huang1,2Liang Li,Liang Li1,2Qiang Zhang,Qiang Zhang1,2Qinye Fu,Qinye Fu1,2Zhongbing Ma,Zhongbing Ma1,2Dezong Gao,Dezong Gao1,2Shude CuiShude Cui7Cuizhi GengCuizhi Geng8Xuchen CaoXuchen Cao9Zhenlin YangZhenlin Yang10Xiang WangXiang Wang11Hong LiangHong Liang12Hongchuan JiangHongchuan Jiang13Haibo WangHaibo Wang14Guolou LiGuolou Li15Qitang WangQitang Wang16Jianguo ZhangJianguo Zhang17Feng JinFeng Jin18Jinhai TangJinhai Tang19Fuguo TianFuguo Tian20Chunmiao Ye,Chunmiao Ye1,3Zhigang Yu, Zhigang Yu1,21*
  • 1Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China
  • 2Institute of Translational Medicine of Breast Disease Prevention and Treatment, Shandong University, Jinan, China
  • 3School of Medicine, Shandong University, Jinan, China
  • 4Breast Disease Center, Peking University First Hospital, Beijing, China
  • 5Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China
  • 6Breast Disease Center, Peking University People's Hospital, Beijing, China
  • 7Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China
  • 8Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
  • 9Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  • 10Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Binzhou Medical University, Binzhou, China
  • 11Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
  • 12Department of General Surgery, Linyi People's Hospital, Linyi, China
  • 13Department of General Surgery, Beijing Chaoyang Hospital, Beijing, China
  • 14Breast Center, Qingdao University Affiliated Hospital, Qingdao, China
  • 15Department of Breast and Thyroid Surgery, Weifang Traditional Chinese Hospital, Weifang, China
  • 16Department of Breast Surgery, The Second Affiliated Hospital of Qingdao Medical College, Qingdao Central Hospital, Qingdao, China
  • 17Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
  • 18Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China
  • 19Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital Cancer Institute of Jiangsu Province, Nanjing, China
  • 20Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan, China
  • 21Suzhou Institute, Shandong University, Suzhou, China

An Addendum on
Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women

by Xiang, Y., Zhou, W., Duan, X., Fan, Z., Wang, S., Liu, S., et al. (2020) Front. Endocrinol. 10:905. doi: 10.3389/fendo.2019.00905

In the original article, there were mistakes in Table 6, Table 7, Table 9 as published. The numbers of patients in Table 6 and Table 9 were incorrect. The contents in Table 7 and Table 9 were repetitive to some degree in that we had shown the association between adiponectin with metabolic syndrome and HW phenotype. Therefore, for this Correction, we analyzed the association between adiponectin and metabolic syndrome, and the association in pre- and postmenopausal subgroups in Table 7. In Table 9, we converted the numerical variable into categorical variable, which should provide better guide for clinical practice. In our view, this avoids the repetition. These new tables appear below as Tables 6, 7, 9. The authors apologize for these errors and any confusion that may have arisen due to them and hopes these additional tables sufficiently addresses them.

TABLE 6
www.frontiersin.org

Table 6. Association between HW phenotype and breast cancer by logistic regression.

TABLE 7
www.frontiersin.org

Table 7. Association between total adiponectin, HMW adiponectin, HMW/total ratio, and metabolic syndrome.

TABLE 9
www.frontiersin.org

Table 9. The association among metabolic syndrome, breast cancer, and adiponectin.

In the original article, corresponding text of Table 6, Table 7, and Table 9 was corrected.

A correction has been made to Abstract, Results, Paragraph number 1:

In addition, total adiponectin levels among breast cancer patients were much lower than among controls (p = 0.005) only in the HW phenotype subgroup. Furthermore, the HW phenotype was associated with increased risk of estrogen receptor/progesterone receptor-positive (ER+/PR+) breast cancer, with a 95% (OR = 1.95, 95% CI:1.21–3.13) increase. However, there was no significant association between the HW phenotype and both ER+/PR– and ER–/PR– subtypes.

A correction has been made to Results, Cluster Mode of HW Phenotype Significantly Increases Breast Cancer Risk, Paragraph number 3:

HW phenotype was associated with ER+/PR+ breast cancer, with a 95% (OR = 1.95, 95% CI:1.21–3.13) increase in risk for women with a positive HW phenotype. However, there was no significant association between HW phenotype and both ER+/PR– and ER–/PR– subtypes.

A correction has been made to Results, Adiponectin Might Be the Mechanism Linking Metabolic Syndrome to Breast Cancer, Paragraph number 2:

total adiponectin levels among breast cancer patients were much lower than among the controls(p = 0.005) in the HW phenotype subgroup.

A correction has been made to Results, Adiponectin Might Be the Mechanism Linking Metabolic Syndrome to Breast Cancer, Paragraph number 3:

there was a significant difference of total adiponectin in ER+/PR+ (p = 0.028) and ER–/PR– (p = 0.043) breast cancer compared to the controls, who were much lower in the HW phenotype subgroup.

A correction has been made to Discussion, Paragraph number 6:

We revealed that HW phenotype was an independent risk factor for the ER+/PR+ subtype.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: breast cancer, metabolic syndrome, hypertriglyceridemic-waist phenotype, adiponectin, risk

Citation: Xiang Y, Zhou W, Duan X, Fan Z, Wang S, Liu S, Liu L, Wang F, Yu L, Zhou F, Huang S, Li L, Zhang Q, Fu Q, Ma Z, Gao D, Cui S, Geng C, Cao X, Yang Z, Wang X, Liang H, Jiang H, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Tian F, Ye C and Yu Z (2020) Addendum: Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women. Front. Endocrinol. 11:227. doi: 10.3389/fendo.2020.00227

Received: 28 February 2020; Accepted: 30 March 2020;
Published: 04 June 2020.

Edited and reviewed by: Eva Surmacz, Allysta Pharmaceuticals, Inc., United States

Copyright © 2020 Xiang, Zhou, Duan, Fan, Wang, Liu, Liu, Wang, Yu, Zhou, Huang, Li, Zhang, Fu, Ma, Gao, Cui, Geng, Cao, Yang, Wang, Liang, Jiang, Wang, Li, Wang, Zhang, Jin, Tang, Tian, Ye and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhigang Yu, yzg@medmail.com.cn

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.